For all of Cas9’s potential in research and therapeutics, it—as well as other enzymes in the CRISPR-associated family—has limitations. In order to recognize and bind to a DNA sequence, Cas9 needs a particular stretch of base letters to accompany the target. This requirement makes much of the genome inaccessible to the enzyme, significantly reducing its range of applications.